Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

Pipeline

Pipeline

Overview
Piclidenoson
Namodenoson
CF602
 

Overview

Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent safety.

 

Piclidenoson (CF101), Can-Fite’s first candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug.


Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria, for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

 

 

Committed to develop highly
specific life changing drugs


Namodenoson (CF102), Can-Fite’s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH).


Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.
 

CF602, an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of erectile dysfunction.